Form 4: Labcorp Executive Granted Stock Options, RSUs

Labcorp Holdings Inc. EVP Megan D. Bailey received grants of non-qualified stock options and restricted stock units on February 10, 2026, aligning her interests with shareholder value.

Summary

• Megan D. Bailey, EVP, President, Central Labs & International at Labcorp Holdings Inc. (LH), was granted equity awards.
• On February 10, 2026, Bailey received 3,300 non-qualified stock options with an exercise price of $284.50 per share.
• These stock options will vest in three equal annual installments, beginning on February 10, 2027, and expire on February 9, 2036.
• Also on February 10, 2026, Bailey was granted 1,100 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The RSUs will vest in three equal annual installments, beginning on February 10, 2027.
• Following these transactions, Bailey beneficially owns 3,300 non-qualified stock options and an aggregate of 3,230 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value.

Positives

• The grants align executive compensation with shareholder interests, as the value of options and RSUs is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and performance from a key executive.
• The grants are part of the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an equity grant.

Future Outlook

The grants of stock options and Restricted Stock Units include multi-year vesting schedules, with the first installments beginning on February 10, 2027. This structure incentivizes the executive's continued performance and long-term commitment to Labcorp's success, with stock options expiring on February 9, 2036.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and Restricted Stock Units, are standard components of executive compensation packages across the healthcare and diagnostics industry. These grants are designed to align the interests of executives with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• Executive equity grants are a common practice in publicly traded companies, particularly within the healthcare sector, to attract, retain, and motivate key leadership.
• The vesting schedule of three equal annual installments is a typical structure, similar to practices at peers like Quest Diagnostics (DGX) or other large diagnostic service providers, promoting sustained performance over several years.
• The use of both stock options and Restricted Stock Units provides a balanced incentive, offering upside potential with options and retention value with RSUs, consistent with broad market compensation trends.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the executive's financial interests with shareholder value creation, as the awards' value is tied to the company's stock performance.
• Employees: The use of an omnibus incentive plan demonstrates the company's commitment to incentivizing key personnel, potentially boosting morale and retention.

Next Steps

• First vesting of non-qualified stock options on February 10, 2027.
• First vesting of Restricted Stock Units on February 10, 2027.
• Subsequent annual vesting installments for both awards.
• Potential exercise of stock options by Megan D. Bailey prior to the February 9, 2036 expiration.

Key Dates

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSU, Executive Compensation, Equity Grant, Megan D. Bailey